Akoya Biosciences - AKYA Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKYA shares.
View AKYA analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 1 year target prices for Akoya Biosciences' stock. Their AKYA share price forecasts range from $13.00 to $19.00. On average, they anticipate the company's stock price to reach $16.17 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts price targets for AKYA or view top-rated stocks among Wall Street analysts.

Akoya Biosciences' stock was trading at $9.57 at the beginning of 2023. Since then, AKYA stock has decreased by 14.5% and is now trading at $8.18.
View the best growth stocks for 2023 here.

Akoya Biosciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 722,700 shares, an increase of 45.1% from the February 28th total of 498,000 shares. Based on an average daily trading volume, of 131,100 shares, the short-interest ratio is currently 5.5 days. Currently, 4.3% of the shares of the stock are sold short.
View Akoya Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AKYA earnings forecast.

Akoya Biosciences, Inc. (NASDAQ:AKYA) posted its earnings results on Monday, March, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.09. The company had revenue of $21.22 million for the quarter, compared to analysts' expectations of $20.85 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 85.35% and a negative net margin of 94.36%. During the same period in the previous year, the company posted ($0.47) earnings per share.

ETFs with the largest weight of Akoya Biosciences (NASDAQ:AKYA) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC).

Akoya Biosciences issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95.00 million-$98.00 million, compared to the consensus revenue estimate of $93.08 million.

(AKYA) raised $125 million in an IPO on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO.

Akoya Biosciences trades on the NASDAQ under the ticker symbol "AKYA."

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKYA stock can currently be purchased for approximately $8.18.

Akoya Biosciences (NASDAQ:AKYA) has a market capitalization of $313.62 million and generates $74.86 million in revenue each year. The company earns $-70,640,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

The company employs 319 workers across the globe.

The official website for the company is www.akoyabio.com. The company can be reached via phone at 855-896-8401 or via email at investors@akoyabio.com.